Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1 g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis

Journal of Antimicrobial Chemotherapy

Volumn 47, Issue 1, 2001, Pages 67-76

  Georgopoulos, A ^a   Borek, M ^b   Ridl, W ^b   Holzer, R ^c   Thomuller I ^c   Vetter, N ^c   Artner, H ^c   Wallner, G ^c   Hutter, C ^c   Rath, J ^c   Kohuot, E ^c   Gitsch, G ^c   Feichtinger, I ^c   Flicker, M ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CANDIDIASIS; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; MYCOSIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 0035185816     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/47.1.67     Document Type: Article

References (38)

1. The role of antimicrobial therapy in acute exacerbation of chronic bronchitis
2. Defining subsets of patients with chronic bronchitis
3. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function
4. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis
5. Chemotherapy for chronic bronchitis. Controversies
6. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis
7. Treatment of acute exacerbations of chronic bronchitis: Comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group
8. Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis
9. Fleroxacin versus amoxicillin in the treatment of acute exacerbation of chronic bronchitis
10. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis
11. Loracarbef (LY163892) in the treatment of acute exacerbations of chronic bronchitis: Results of U.S. and European comparative clinical trials
12. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
13. Antimicrobial resistance issues of the future
14. Ascertaining how much compliance is enough with outpatient antibiotic regimens
15. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
16. Resistance patterns of Haemophilus influenzae
17. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance Study
18. Basing empiric treatment choices for respiratory tract infection on the results of the Alexander Project
19. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: The Alexander Project
20. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection
21. A randomized double blind controlled trial comparing two amoxycillin regimens in the treatment of acute exacerbations of chronic bronchitis
22. Comparative study of two formulations and two dosage regimens of amoxicillin in the treatment of exacerbations of chronic bronchitis
23. Amoxycillin in bronchitis. Comparison of two versus three daily doses
24. Treatment of acute pyelonephritis using two dosage regimens of amoxicillin
25. General guidelines for the clinical evaluation of anti-infective drug products. Infectious Diseases Society of America and the Food and Drug Administration
26. 6-day amoxicillin versus 10-day penicillin V for group A β-haemolytic streptococcal acute tonsillitis in adults: A French multicentre, open-label, randomized study
27. Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis
28. Treatment of acute maxillary sinusitis-comparing cefpodoxime proxetil with amoxicillin
29. A controlled, multicentre study comparing cefixime and amoxycillin in the treatment of lower respiratory tract infections in adults
30. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report
31. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis
32. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: Comparison with a 10-day course of 500 milligrams twice daily
33. Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis
34. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis
35. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice
36. The microbiological eradication rate of first-line antibiotic treatment is a key cost driver in the treatment of acute bacterial exacerbations of chronic bronchitis
37. The Nearchus project: Antibiotic susceptibility of respiratory pathogens and clinical outcome in lower respiratory tract infections at 27 centres in the UK
38. Factors affecting nonadherence with antibiotics